IPP Bureau
.jpg "Cipla to sell Lilly's weight-loss drug under new brand in India")
Cipla to sell Lilly's weight-loss drug under new brand in India
By IPP Bureau - October 24, 2025
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
AstraZeneca's imfinzi cuts death risk by 22% in early gastric cancer
By IPP Bureau - October 24, 2025
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Laurus Labs posts Q2 FY26 consolidated PAT higher at Rs. 195 Cr
By IPP Bureau - October 24, 2025
Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025
Caplin Steriles receives FDA approval for ANDA Nicardipine Hydrochloride in 0.9% Sodium Chloride injection
By IPP Bureau - October 24, 2025
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
IMCD showcases patient-centric pharmaceutical solutions at CPHI Frankfurt 2025
By IPP Bureau - October 24, 2025
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
Lupin launches authorized generic of Ravicti in US
By IPP Bureau - October 24, 2025
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP
By IPP Bureau - October 23, 2025
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Moderna discontinues congenital virus program after Phase 3 trial fails to meet primary endpoint
By IPP Bureau - October 23, 2025
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Ipsen to acquire ImCheck Therapeutics to strengthen oncology pipeline
By IPP Bureau - October 23, 2025
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Takeda and Innovent Biologics forge global partnership to advance oncology medicines for solid tumors
By IPP Bureau - October 23, 2025
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV
By IPP Bureau - October 23, 2025
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
FDA grants priority review to Merck’s KEYTRUDA and KEYTRUDA QLEX combos with Padcev for muscle-invasive bladder cancer
By IPP Bureau - October 23, 2025
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
By IPP Bureau - October 23, 2025
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
ACG to invest $200 million in US hard-shell capsule manufacturing
By IPP Bureau - October 22, 2025
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
FDA approves Roche’s kidney inflammation drug
By IPP Bureau - October 22, 2025
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
